Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02824523 · ClinicalTrials.gov registry record
Role of Inflammatory Mediators in AERD
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 40
- Enrollment target
NCT02824523 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 40 participants.
The verdict
NCT02824523 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
The purpose of this research study is to learn new information about the underlying cause of aspirin-exacerbated respiratory disease (AERD) and the benefit of high-dose aspirin therapy. AERD is a disease that involves asthma, recurring nasal polyps, and respiratory reactions to aspirin and other nonsteroidal anti-inflammatory drugs. This study will be conducted on individuals with AERD who are referred to the Brigham and Women's Hospital AERD Center for clinical evaluation and potential aspirin desensitization. Desensitization to aspirin and subsequent treatment with daily high-dose oral aspirin is standard of care for patients with AERD who do not respond adequately to steroids and have recurrent nasal polyposis or symptomatic asthma. This study will involve five visits to Brigham and Women's Hospital and will align closely with the standard of care for the treatment of AERD.
Interventions
- DRUG aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-07 |
| Est. Completion | 2021-05-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02824523
The ClinicalTrials.gov registry entry for NCT02824523 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aspirin is the first listed.
NCT02824523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02824523 about?
NCT02824523 is a clinical study titled "Role of Inflammatory Mediators in AERD". The purpose of this research study is to learn new information about the underlying cause of aspirin-exacerbated respiratory disease (AERD) and the benefit of high-dose aspirin therapy. AERD is a disease that involves asthma, recurring nasal polyps, and respiratory reactions to aspirin and other non...
What is the current status of trial NCT02824523?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2016-07. Estimated completion is 2021-05-01.
What interventions are being tested in trial NCT02824523?
The interventions under investigation include: aspirin (DRUG).
Who is sponsoring clinical trial NCT02824523?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.